BioCentury | Mar 15, 2019
Clinical News

ViiV planning submissions this year for two-drug HIV regimen

...endpoint, switching to cabotegravir plus Edurant every four weeks was non-inferior to continuing once-daily oral Triumeq...
...vs. 2.5%). The trial enrolled 566 patients who were virologically suppressed after receiving once-daily oral Triumeq...
...reverse transcriptase inhibitor (NNRTI), to treat HIV-1 infection in combination with other antiretroviral agents. ViiV’s Triumeq...
BioCentury | Nov 2, 2018
Clinical News

ViiV's two-drug HIV regimen meets again in Phase III

...endpoint, ViiV said switching to cabotegravir and Edurant showed similar efficacy to continuing once-daily oral Triumeq...
...once-daily oral Triumeq for 20 weeks. After the induction phase, patients either continued on once-daily Triumeq...
...Phase III data Milestone: NA Jaime De Leon cabotegravir (GSK1265744, s/gsk1265744, s-1265744) Edurant, rilpivirine (TMC278) Triumec, Triumeq, dolutegravir/abacavir/lamivudine (S-349572/S-265744/S-247303, 572-trii) GlaxoSmithKline...
BioCentury | Jun 1, 2018
Clinical News

FDA issues MedWatch safety alert for dolutegravir

...Tivicay, in a double combination as Juluca dolutegravir/rilpivirine, and in a triple combination as Triumeq dolutegravir/abacavir/lamivudine...
...Compound #), S-349572 (Former compound #), dolutegravir (Generic), Tivicay (Other), 1349572 (Other) Triumec, Triumeq, dolutegravir/abacavir/lamivudine (S-349572/S-265744/S-247303, 572-trii) ViiV...
BioCentury | Mar 9, 2018
Clinical News

Gilead reports additional Phase III data from HIV switching trial of Biktarvy

...adults with HIV-1 infection showing that switching from either Tivicay dolutegravir plus abacavir/lamivudine or Triumeq dolutegravir/abacavir/lamivudine...
...the primary endpoint, of 1.1% vs. 0.4% for patients remaining on Tivicay plus abacavir/lamivudine or Triumeq...
...48, a secondary endpoint, vs. 95% of patients who remained on Tivicay plus abacavir/lamivudine or Triumeq...
BioCentury | Sep 22, 2017
Clinical News

China FDA approves ViiV's HIV drug Triumeq

...approved Triumeq dolutegravir/abacavir/lamivudine (Triumec, 572-Trii, S-349572/S-265744/S-247303) from ViiV Healthcare Ltd. (Brentford, U.K.) to treat HIV/AIDS. Triumeq...
...Brentford, U.K. Product: Triumeq dolutegravir/ abacavir/lamivudine ( Triumec , 572-Trii , S-349572/S-265744/S-247303) Business: Infectious Chris Lieu 572-Trii dolutegravir/abacavir/lamivudine S-349572/S-265744/S-247303 Triumec Triumeq GlaxoSmithKline...
BioCentury | Jun 2, 2017
Clinical News

Gilead reports Phase III data for HIV combo in virologically suppressed patients

...alafenamide or stay on their existing regimen of either Tivicay dolutegravir plus abacavir/lamivudine or Triumeq dolutegravir/abacavir/lamivudine...
BioCentury | Jun 2, 2017
Clinical News

Gilead reports Phase III data for HIV combo in treatment-naïve patients

...MAA to EMA in 3Q17 for the combination. In GS-US-380-1489, bictegravir/emtricitabine/tenofovir alafenamide was non-inferior to Triumeq...
BioCentury | May 30, 2017
Clinical News

Gilead’s HIV combo non-inferior in four Phase III trials

...the proportion of patients with HIV-1 RNA levels <50 copies/mL at week 48. Comparators included Triumeq...
BioCentury | Nov 30, 2016
Clinical News

Cabotegravir: Ph III started

...oral Triumeq dolutegravir/abacavir/lamivudine in about 600 treatment-naïve patients. After induction, patients will either continue on Triumeq...
BioCentury | Aug 1, 2016
Clinical News

Triumeq dolutegravir/abacavir/lamivudine: Phase IIIb data

...ARIA trial in 495 antiretroviral therapy (ART)-naive women with HIV-1 infection showed that once-daily oral Triumeq...
...71%, p=0.005). ViiV said ARIA was a non-inferiority study with a pre-specified analysis for superiority. Triumeq...
...ViiV. ViiV Healthcare Ltd. , Brentford, U.K. Product: Triumeq dolutegravir/ abacavir/lamivudine ( 572-Trii ) ( S-349572/S-265744/S-247303...
Items per page:
1 - 10 of 22